Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.

Néant N, Solas C, Bouazza N, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Gattacceca F.

J Antimicrob Chemother. 2019 Jul 1;74(7):1992-2002. doi: 10.1093/jac/dkz141.

PMID:
31225609
2.

From 3D spheroids to tumor bearing mice: efficacy and distribution studies of trastuzumab-docetaxel immunoliposome in breast cancer.

Rodallec A, Sicard G, Giacometti S, Carré M, Pourroy B, Bouquet F, Savina A, Lacarelle B, Ciccolini J, Fanciullino R.

Int J Nanomedicine. 2018 Oct 23;13:6677-6688. doi: 10.2147/IJN.S179290. eCollection 2018. Erratum in: Int J Nanomedicine. 2018 Dec 31;14:335.

3.

Turning cold tumors into hot tumors: harnessing the potential of tumor immunity using nanoparticles.

Rodallec A, Sicard G, Fanciullino R, Benzekry S, Lacarelle B, Milano G, Ciccolini J.

Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1139-1147. doi: 10.1080/17425255.2018.1540588. Epub 2018 Oct 29. Review.

4.

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies.

Madelain V, Baize S, Jacquot F, Reynard S, Fizet A, Barron S, Solas C, Lacarelle B, Carbonnelle C, Mentré F, Raoul H, de Lamballerie X, Guedj J.

Nat Commun. 2018 Oct 1;9(1):4013. doi: 10.1038/s41467-018-06215-z.

5.

Pharmacokinetics variability: Why nanoparticles are not just magic-bullets in oncology.

Rodallec A, Benzekry S, Lacarelle B, Ciccolini J, Fanciullino R.

Crit Rev Oncol Hematol. 2018 Sep;129:1-12. doi: 10.1016/j.critrevonc.2018.06.008. Epub 2018 Jun 19. Review.

PMID:
30097227
6.

Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.

Rodallec A, Brunel JM, Giacometti S, Maccario H, Correard F, Mas E, Orneto C, Savina A, Bouquet F, Lacarelle B, Ciccolini J, Fanciullino R.

Int J Nanomedicine. 2018 Jun 18;13:3451-3465. doi: 10.2147/IJN.S162454. eCollection 2018.

7.

"No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon!

Milano G, Innocenti F, Lacarelle B, Ciccolini J.

Crit Rev Oncol Hematol. 2018 Jul;127:1-5. doi: 10.1016/j.critrevonc.2018.04.003. Epub 2018 Apr 17. Review.

PMID:
29891106
8.

Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.

Rodallec A, Fanciullino R, Lacarelle B, Ciccolini J.

Expert Rev Clin Pharmacol. 2018 Jun;11(6):599-610. doi: 10.1080/17512433.2018.1477586. Epub 2018 May 24. Review.

PMID:
29768060
9.

Cannabis smoking impairs driving performance on the simulator and real driving: a randomized, double-blind, placebo-controlled, crossover trial.

Micallef J, Dupouey J, Jouve E, Truillet R, Lacarelle B, Taillard J, Daurat A, Authié C, Blin O, Rascol O, Philip P, Mestre D.

Fundam Clin Pharmacol. 2018 Oct;32(5):558-570. doi: 10.1111/fcp.12382. Epub 2018 Jun 6.

PMID:
29752828
10.

Proof of concept: prognostic value of the plasmatic concentration of circulating cell free DNA in desmoid tumors using ddPCR.

Macagno N, Fina F, Penel N, Bouvier C, Nanni I, Duffaud F, Rouah R, Lacarelle B, Ouafik L, Bonvalot S, Salas S.

Oncotarget. 2018 Apr 6;9(26):18296-18308. doi: 10.18632/oncotarget.24817. eCollection 2018 Apr 6.

11.

CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.

Fanciullino R, Farnault L, Donnette M, Imbs DC, Roche C, Venton G, Berda-Haddad Y, Ivanov V, Ciccolini J, Ouafik L, Lacarelle B, Costello R.

Blood Adv. 2018 Mar 13;2(5):462-469. doi: 10.1182/bloodadvances.2017014126. Erratum in: Blood Adv. 2018 May 8;2(9):1013.

12.

Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.

Néant N, Gattacceca F, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C.

Eur J Clin Pharmacol. 2018 Apr;74(4):473-481. doi: 10.1007/s00228-017-2405-1. Epub 2018 Jan 26.

PMID:
29374296
13.

Revisiting Bevacizumab + Cytotoxics Scheduling Using Mathematical Modeling: Proof of Concept Study in Experimental Non-Small Cell Lung Carcinoma.

Imbs DC, El Cheikh R, Boyer A, Ciccolini J, Mascaux C, Lacarelle B, Barlesi F, Barbolosi D, Benzekry S.

CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):42-50. doi: 10.1002/psp4.12265. Epub 2017 Dec 7.

14.

Plasma 7-Hydroxymethotrexate Levels Versus Methotrexate to Predict Delayed Elimination in Children Receiving High-Dose Methotrexate.

Fabresse N, Devictor B, Pissier C, Chambost H, Lacarelle B, Michel G, Solas C.

Ther Drug Monit. 2018 Feb;40(1):76-83. doi: 10.1097/FTD.0000000000000445.

PMID:
29120974
15.

PRIMUM NON NOCERE: now and again an echo of DPD with capecitabine.

Ciccolini J, Lacarelle B, Milano G.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1265-1266. doi: 10.1007/s00280-017-3437-z. Epub 2017 Oct 13. No abstract available.

PMID:
29030673
16.

Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.

Solas C, Bregigeon S, Faucher-Zaegel O, Quaranta S, Obry-Roguet V, Tamalet C, Lacarelle B, Poizot-Martin I.

Br J Clin Pharmacol. 2018 Feb;84(2):404-409. doi: 10.1111/bcp.13450. Epub 2017 Nov 28.

17.

A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients.

Becher F, Ciccolini J, Imbs DC, Marin C, Fournel C, Dupuis C, Fakhry N, Pourroy B, Ghettas A, Pruvost A, Junot C, Duffaud F, Lacarelle B, Salas S.

Sci Rep. 2017 Jun 2;7(1):2714. doi: 10.1038/s41598-017-02821-x.

18.

Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients.

Barlesi F, Imbs DC, Tomasini P, Greillier L, Galloux M, Testot-Ferry A, Garcia M, Elharrar X, Pelletier A, André N, Mascaux C, Lacarelle B, Cheikh RE, Serre R, Ciccolini J, Barbolosi D.

Oncotarget. 2017 Jul 18;8(29):47161-47166. doi: 10.18632/oncotarget.17562.

19.

Daclatasvir plasma concentration assessment in HIV-HCV-coinfected real-life patients.

Taton A, Colson P, Dhiver C, Ruiz JM, Bregigeon S, Tomei C, Ressiot E, Menard A, Poizot-Martin I, Ravaux I, Lacarelle B, Solas C.

Antivir Ther. 2017;22(8):731-733. doi: 10.3851/IMP3163. No abstract available.

PMID:
28362269
20.

Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.

Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L.

Ther Drug Monit. 2017 Jun;39(3):290-296. doi: 10.1097/FTD.0000000000000399.

PMID:
28346313
21.

Population pharmacokinetics model of THC used by pulmonary route in occasional cannabis smokers.

Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O.

J Pharmacol Toxicol Methods. 2017 May - Jun;85:49-54. doi: 10.1016/j.vascn.2017.02.003. Epub 2017 Feb 4.

PMID:
28167229
22.

UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS.

Launay M, Ciccolini J, Fournel C, Blanquicett C, Dupuis C, Fakhry N, Duffaud F, Salas S, Lacarelle B.

Clin Cancer Drugs. 2017;4(2):122-128. doi: 10.2174/2212697x04666170817123425.

23.

Comparison of Cannabinoid Concentrations in Plasma, Oral Fluid and Urine in Occasional Cannabis Smokers After Smoking Cannabis Cigarette.

Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O.

J Pharm Pharm Sci. 2016 Jul - Sep;19(3):411-422. doi: 10.18433/J3F31D.

24.

ITPA deficiency and ribavirin level are still predictive of anaemia in HCV-HIV-coinfected patients receiving ribavirin combined with a first-generation DAA (ANRS HC27 study).

Kheloufi F, Poizot-Martin I, Garraffo R, Tavenard A, Quaranta S, Renault A, Lavrut T, Bourlière M, Halfon P, Piroth L, Bellissant E, Lacarelle B, Molina JM, Solas C; ANRS HC27 BOCEPREVIH Study Group.

Antivir Ther. 2017;22(6):461-469. doi: 10.3851/IMP3074. Epub 2016 Sep 1.

PMID:
27583701
25.

Nucleoside analogs: ready to enter the era of precision medicine?

Ciccolini J, Serdjebi C, Le Thi Thu H, Lacarelle B, Milano G, Fanciullino R.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):865-77. doi: 10.1080/17425255.2016.1192128. Epub 2016 May 30. Review.

PMID:
27218825
26.

Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV-hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy.

Kheloufi F, Bellissant E, Cotte L, Poizot-Martin I, Quaranta S, Garraffo R, Barrail-Tran A, Renault A, Fournier I, Lacarelle B, Bourlière M, Molina JM, Solas C; ANRS HC27 BOCEPREVIH & HC26 TELAPREVIH Study Groups.

AIDS. 2016 Aug 24;30(13):2085-90. doi: 10.1097/QAD.0000000000001143.

PMID:
27149089
27.

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol.

Elharrar X, Barbolosi D, Ciccolini J, Meille C, Faivre C, Lacarelle B, André N, Barlesi F.

BMC Cancer. 2016 Apr 20;16:278. doi: 10.1186/s12885-016-2308-z.

28.

Monoclonal antibodies for treating gastric cancer: promises and pitfalls.

Sibertin-Blanc C, Ciccolini J, Norguet E, Lacarelle B, Dahan L, Seitz JF.

Expert Opin Biol Ther. 2016 Jun;16(6):759-69. doi: 10.1517/14712598.2016.1164137. Epub 2016 Mar 25. Review.

PMID:
26971395
29.

Computational oncology--mathematical modelling of drug regimens for precision medicine.

Barbolosi D, Ciccolini J, Lacarelle B, Barlési F, André N.

Nat Rev Clin Oncol. 2016 Apr;13(4):242-54. doi: 10.1038/nrclinonc.2015.204. Epub 2015 Nov 24. Review.

PMID:
26598946
30.

Yin and yang of cytidine deaminase roles in clinical response to azacitidine in the elderly: a pharmacogenetics tale.

Fanciullino R, Mercier C, Serdjebi C, Venton G, Colle J, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenomics. 2015 Nov;16(17):1907-12. doi: 10.2217/pgs.15.135. Epub 2015 Nov 10.

PMID:
26556583
31.

Beating the odds: efficacy and toxicity of dihydropyrimidine dehydrogenase-driven adaptive dosing of 5-FU in patients with digestive cancer.

Launay M, Dahan L, Duval M, Rodallec A, Milano G, Duluc M, Lacarelle B, Ciccolini J, Seitz JF.

Br J Clin Pharmacol. 2016 Jan;81(1):124-30. doi: 10.1111/bcp.12790. Epub 2015 Nov 28.

32.

Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine.

Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlési F, André N, Ciccolini J.

Semin Cancer Biol. 2015 Dec;35:53-61. doi: 10.1016/j.semcancer.2015.09.002. Epub 2015 Sep 7. Review.

PMID:
26361213
33.

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.

Ciccolini J, Benzekry S, Lacarelle B, Barbolosi D, Barlési F.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16. No abstract available.

34.

Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.

Fanciullino R, Mercier C, Serdjebi C, Berda Y, Fina F, Ouafik L, Lacarelle B, Ciccolini J, Costello R.

Pharmacogenet Genomics. 2015 Jun;25(6):317-21. doi: 10.1097/FPC.0000000000000139.

PMID:
25850965
35.

Ang1 and Tie2 are predictive biomarkers for bevacizumab-letter.

Ciccolini J, Serdjebi C, Barbolosi D, Lacarelle B, Barlesi F.

Clin Cancer Res. 2015 Feb 15;21(4):934. doi: 10.1158/1078-0432.CCR-14-2832. No abstract available.

36.

[Clinical application, limits and perspectives of pharmacogenetic and pharmacokinetic analysis of anticancer drugs].

Chantry AS, Quaranta S, Ciccolini J, Lacarelle B.

Ann Biol Clin (Paris). 2014 Sep-Oct;72(5):527-42. doi: 10.1684/abc.2014.0993. Review. French.

37.

[Triazole antifungal agents: practice guidelines of therapeutic drug monitoring and perspectives in treatment optimization].

Scodavolpe S, Quaranta S, Lacarelle B, Solas C.

Ann Biol Clin (Paris). 2014 Jul-Aug;72(4):391-404. doi: 10.1684/abc.2014.0968. Review. French.

38.

Metronomics chemotherapy: time for computational decision support.

Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B, André N, Barlesi F.

Cancer Chemother Pharmacol. 2014 Sep;74(3):647-52. doi: 10.1007/s00280-014-2546-1. Epub 2014 Aug 1. Review.

PMID:
25082520
39.

Recipient/donor contradictory genotypes with impact on drug pharmacogenetics after liver transplant: a deadly gift?

Serdjebi C, Ciccolini J, Fina F, Delarue A, Verschuur A, Lacarelle B, Ouafik L, André N.

Pharmacogenet Genomics. 2014 Oct;24(10):527-9. doi: 10.1097/FPC.0000000000000076.

PMID:
25003625
40.

Severe decrease of cyclosporine levels in a heart transplant recipient receiving the direct thrombin inhibitor argatroban.

Sanchez R, Picard N, Mouly-Bandini A, Chalvignac V, Lacarelle B, Sampol-Manos E.

Ther Drug Monit. 2014 Jun;36(3):273-7. doi: 10.1097/FTD.0000000000000026.

PMID:
24365983
41.

Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.

Serdjebi C, Seitz JF, Ciccolini J, Duluc M, Norguet E, Fina F, Lacarelle B, Ouafik L, Dahan L.

Pharmacogenomics. 2013 Jul;14(9):1047-51. doi: 10.2217/pgs.13.93.

PMID:
23837479
42.

Severe or lethal toxicities with nucleosidic analogs: time for action.

Evrard A, Lacarelle B, Ciccolini J.

Pharmacogenomics. 2013 Feb;14(3):227-30. doi: 10.2217/pgs.12.208. No abstract available.

43.

HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.

Perrin S, Cremer J, Faucher O, Reynes J, Dellamonica P, Micallef J, Solas C, Lacarelle B, Stretti C, Kaspi E, Robaglia-Schlupp A, Nicolino-Brunet C, Tamalet C, Lévy N, Poizot-Martin I, Cau P, Roll P.

PLoS One. 2012;7(12):e53035. doi: 10.1371/journal.pone.0053035. Epub 2012 Dec 28. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/f02cdfd3-b271-46fd-a78f-5a030f0b416d. Tamalet, Corine Nicolino-Brunet Catherine [corrected to Nicolino-Brunet, Corinne]; [ corrected to Tamalet, Catherine].

44.

Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration.

Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):375-80. doi: 10.1097/QAI.0b013e31827ce4ee.

PMID:
23196828
45.

Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.

Woloch C, Di Paolo A, Marouani H, Bocci G, Ciccolini J, Lacarelle B, Danesi R, Iliadis A.

Curr Top Med Chem. 2012;12(15):1713-9.

PMID:
22978343
46.

100% human monoclonal antibodies in oncology: hype or breakthrough?

Benay S, Fanciullino R, Mercier C, Iliadis A, Ciccolini J, Lacarelle B.

Curr Top Med Chem. 2012;12(15):1643-8. Review.

PMID:
22978333
47.

[Recommendations for the prescription, implementation and interpretation of medical examinations in biology in the context of severe poisoning].

Bartoli M, Berny C, Danel V, Delahaye A, Desch G, Guitton J, Lacarelle B, Lapostolle F, Mathieu D, Mégarbane B, Nisse P, Szymanowicz A, Capolaghi B; Toxicology and Clinical Biology Working Group.

Ann Biol Clin (Paris). 2012 Jul-Aug;70(4):431-50. French.

48.

CDA deficiency as a possible culprit for life-threatening toxicities after cytarabine plus 6-mercaptopurine therapy: pharmacogenetic investigations.

Ciccolini J, Evrard A, M'Batchi L, Pourroy B, Mercier C, Iliadis A, Lacarelle B, Verschuur A, Ouafik L, André N.

Pharmacogenomics. 2012 Mar;13(4):393-7. doi: 10.2217/pgs.11.175.

PMID:
22379997
49.

Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy.

Crocchiolo R, Ciccolini J, El-Cheikh J, Fürst S, Castagna L, Granata A, Oudin C, Harbi S, Devillier R, Legall S, Ternant D, Paintaud G, Lacarelle B, Blaise D.

Leuk Lymphoma. 2012 Oct;53(10):2063-5. doi: 10.3109/10428194.2012.670232. Epub 2012 Apr 19. No abstract available.

PMID:
22372847
50.

A CDD polymorphism as predictor of capecitabine-induced hand-foot syndrome--letter.

Ciccolini J, Evrard A, Lacarelle B.

Clin Cancer Res. 2012 Jan 1;18(1):317. doi: 10.1158/1078-0432.CCR-11-1360. No abstract available.

Supplemental Content

Loading ...
Support Center